A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS) · Smoldering Multiple Myeloma (SMM)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 116 (planned)
- Started
- Sep 16, 2024
- Main results expected
- May 18, 2032
- Fully finished
- May 18, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Frequency of Adverse Events Interest (AEI) during the safety observation period
Measured over: 35 days
Frequency of Treatment-Emergent Adverse Event (TEAEs) during the safety observation period
Measured over: 35 days
Severity of TEAEs during the safety observation period
Measured over: 35 days
Achievement of Complete Response (CR) as determined by the investigator
Measured over: Up to 5.5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06140524 · record last updated 2026-07-08 · checked 2026-11-09 15:47 UTC